PROK vs VCEL
PROK: ProKidney is pioneering a first-in-class autologous kidney cell therapy to slow kidney function decline in advanced CKD and diabetes patients, currently in Phase 3 trials with FDA RMAT designation. VCEL: Vericel is a leader in advanced autologous cell therapies for sports medicine and severe burn care, with FDA-approved products MACI for cartilage repair and Epicel for severe burns.
Side-by-side fundamentals
| Metric | PROK | VCEL | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $1.54 | $45.32 | |
| Market cap as of 2026-07-31 | $477M | $2.3B | |
| P/E as of 2026-07-31 | n/a | 117.19 | |
| PEG as of 2026-07-31 | n/a | 0.12 | |
| Net margin as of 2026-07-31 | -8131.5% | +7.3% | VCEL higher |
| Gross margin as of 2026-07-31 | n/a | +74.8% | |
| Operating margin as of 2026-07-31 | -18959.7% | +5.4% | VCEL higher |
| ROE as of 2026-07-31 | -28.1% | +6.4% | VCEL higher |
| ROA as of 2026-07-31 | -21.4% | +4.6% | VCEL higher |
| Debt / equity as of 2026-07-31 | 5.40 | 0.00 | VCEL lower |
| Revenue growth (YoY) as of 2026-07-31 | +190.5% | +22.4% | PROK higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +18.9% | |
| Beta as of 2026-07-31 | 1.82 | 1.06 | |
| 1-year return as of 2026-07-27 close | -53.2% | +13.0% | VCEL higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.